124 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Jagiellonian University Medical College
11
Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.
The University of Sydney
8
N-benzoyl-1,5-benzothiazepine and its S-oxide as vasopressin receptor ligands: insight into the active stereochemistry around the seven-membered ring.
Teikyo University
27
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.
F. Hoffmann-La Roche
9
Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
University of Strasburg
40
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).
Glaxosmithkline
67
New, potent, and selective peptidic oxytocin receptor agonists.
Ferring Research Institute
33
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
Glaxosmithkline
27
Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.
Msd
38
The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
Msd
49
Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.
Glaxosmithkline
21
Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.
Glaxosmithkline
18
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
Medical College of Ohio
18
Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.
University of Strasburg
41
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
Glaxosmithkline
5
Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.
Emory University
14
Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
University of Strasburg
26
Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
Schering-Plough Research Institute
11
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
Glaxosmithkline
4
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
Institute Genomics Functional (Igf)
23
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
University of Montpellier
10
Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
Wyeth Research
67
Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
Serono Pharmaceutical Research Institute
10
Design of benzophenone-containing photoactivatable linear vasopressin antagonists: pharmacological and photoreactive properties.
University of Montpellier
25
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Medical College of Ohio
13
Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
University of Montpellier
35
Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.
Merck Research Laboratories
16
Preparation and biological activities of potential vasopressin photoaffinity labels.
University of Sherbrooke
16
Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.
Johnson and Johnson Pharmaceutical Research and Development
32
Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.
Johnson & Johnson Pharmaceutical Research & Development
12
N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists.
Yamanouchi Pharmaceutical
3
Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.
Lehigh University
34
Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.
Pfizer
70
New, potent, selective, and short-acting peptidic V1a receptor agonists.
Ferring Research Institute
22
Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.
Abbott Laboratories
21
Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.
Msd
11
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
University of Montpellier
41
Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.
Msd
1
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
21
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Università
57
Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.
Pfizer
22
Non-peptide oxytocin antagonists: identification and synthesis of a potent camphor aminosuccinimide
TBA
21
Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds.
Adam Mickiewicz University
34
Development of dual V1a/V2 antagonists containing triazolobenzazepine scaffold.
Gedeon Richter Plc
17
Long-Residence Time Peptide Antagonist for the Vasopressin V2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease.
Xuzhou Medical University
16
Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors.
AstraZeneca
70
Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist.
Gedeon Richter Plc
19
Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.
Johnson & Johnson Pharmaceutical Research & Development
7
Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.
Wyeth Research
34
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.
Biocon-Bristol Myers Squibb Research and Development Centre
10
Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity.
The University of Arizona
36
Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity.
Jerini
12
(4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.
Wyeth Research
17
Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
11
2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.
Johnson & Johnson Pharmaceutical Research & Development
28
Structure-activity study of novel tricyclic benzazepine arginine vasopressin antagonists.
Wyeth Research
14
Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists.
Johnson & Johnson Pharmaceutical Research & Development
41
New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives.
Gedeon Richter
14
Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.
Johnson and Johnson Pharmaceutical Research and Development
24
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
Yamanouchi Pharmaceutical
29
Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.
Glaxosmithkline
28
New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.
Gedeon Richter
26
Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
Otsuka Pharmaceutical
17
The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.
Wyeth-Ayerst Research
43
Discovery of Potent, Selective, and Short-Acting Peptidic V
Ferring Research Institute
17
5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists.
Wyeth-Ayerst Research
6
4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.
Wyeth-Ayerst Research
9
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
Tohoku University and Department of Pharmaceutical Sciences
7
Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.
Kanazawa University
12
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.
Merck Research Laboratories
10
Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.
University of Montpellier
26
Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration.
Shanghai Hengrui Pharmaceutical
31
Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.
Rti International
23
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
Wyeth-Ayerst Research
14
Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects.
Calibr At The Scripps Research Institute
67
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
Otsuka Pharmaceutical
3
Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.
Janssen Pharmaceutica
57
Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.
Otsuka Pharmaceutical
11
1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
Merck Research Laboratories
7
A new series of photoactivatable and iodinatable linear vasopressin antagonists.
Upr 9023 Cnrs
7
1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
Merck Research Laboratories
11
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling.
University of Montpellier
37
LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
Umr7200 Cnrs/Universit£
16
Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors.
The University of Sydney
5
Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists.
The University of Sydney
49
Identification and biological evaluation of thiazole-based inverse agonists of RORĪ³t.
Phenex Pharmaceuticals
6
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
Imperial College
69
Potent and selective oxytocin receptor agonists without disulfide bridges.
Takeda Pharmaceutical
9
Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form.
Teikyo University
128
SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
Genentech
23
Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Gilead Sciences
30
Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor
Janssen Pharmaceutica
7
A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.
Utrecht University
9
Synthesis of hybrid molecules of caffeine and eudistomin D and its effects on adenosine receptors.
Hokkaido University
47
Ligand discovery from a dopamine D3 receptor homology model and crystal structure.
University of California San Francisco
13
Selective Inhibition of DNA Replicase Assembly by a Non-natural Nucleotide: Exploiting the Structural Diversity of ATP-Binding Sites
Case Western Reserve University
17
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Duquesne University
9
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
Universite Montpellier Ii